as 35

AS-35 is an orally effective, potent, and selective antagonist of leukotrienes, antagonizing LTC4-, LTD4-, and LTE4-induced ileum contractions with IC50 values of 8 nM, 4 nM, and 3 nM, respectively. It exhibits antiallergic activities.

GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM, respectively.

GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50 value of 1.4 μg in the β-arrestin recruitment assay.GPR35 agonist 3 is used in the study of cancer, type 2 diabetes, and cardiovascular disease.

Compound 82419-35-0, with CAS No. 82419-35-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 82419-35-0 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 13165-35-0, with CAS No. 13165-35-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 13165-35-0 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Menaquinone-7 (Vitamin K2(35)) is a vitamin K2 analog, is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 (Vitamin K2(35)) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins.

Tyrosinase-IN-35 (compound 6g), exhibiting a IC 50 value of 2.09 μM, serves as a more effective inhibitor of human tyrosinase compared to Kojic Acid (IC 50: 16.38 μM). At concentrations of 4 μM and 8 μM, this compound effectively lowers melanin levels in melanoma B16F10 cells in vitro.

LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.

CDK9-IN-35 (compound 10j) acts as an inhibitor of CDK9/CyclinT1, exhibiting an IC50 of 10.2 nM. It also shows an IC50 of 20 nM against the HCT-116 cell line.

SHP2-IN-35 (Compound 3f) functions as an inhibitor of SHP2. It exhibits antiproliferative activity in cancer cell lines RKO, SW480, and CT26, with IC50 values of 5.72 μM, 3.71 μM, and 1.42 μM, respectively. SHP2-IN-35 inhibits the PI3K-Akt signaling pathway, regulates the expression of cell cycle-related genes, and induces mitochondrial autophagy (autophagy). Within the tumor microenvironment (TME), SHP2-IN-35 suppresses the expression of certain cytokines and chemokines, thereby modulating tumor progression.

E3ligaseLigand-Linker Conjugate 35 is an adduct formed by the conjugation of an E3 ligase ligand with a linker, specifically composed of (S,R,S)-AHPC and its corresponding linker. The (S,R,S)-AHPC component is a von Hippel-Lindau (VHL) ligand derived from VH032, capable of recruiting VHL protein. E3ligaseLigand-Linker Conjugate 35 serves as a critical intermediate for the synthesis of complete PROTACs molecules.

RORγt inverse agonist 35 (Compound 22) is an RORγt inverse agonist with an IC50 of 1.51 μM. It significantly inhibits Th17 differentiation and pro-inflammatory characteristics in human CD4+ T cells. This compound can be utilized for research on Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD).

HIV-1 inhibitor-35 (compound 74) is a highly potent inhibitor of the HIV-1 virus, exhibiting EC50 values of 80 nM and 70 nM for LTR and CMV, respectively, in HEK293 cells. Additionally, it demonstrates inhibitory activity against HepG2 liver cancer cells, with a CC50 value of 40 nM, and shows promise as a potential HIV-1 latency reversing agent [1].

Protein Kinase C (19-35) Peptide, acting as a PKC pseudosubstrate inhibitor/region, can potentially inhibit PKC activity by blocking the substrate-binding site within the kinase domain, thereby inactivating the cytoplasmic form of PKC [1] [2].

HCV Peptide (35-44), a core protein of Hepatitis C Virus at positions 35 to 44, functions as an HLA-A2-restricted CTL epitope and inhibits NK cell activity through the KIR2DL2/3 receptor and synergistically through the CD94:NKG2A receptor [1].

Compound HBV-IN-35 (Compound 88) serves as an HBV inhibitor and exhibits anti-HBV activity in both mouse and human hepatocytes with EC50 values of 100 nM and 400 nM, respectively [1].

AChE-IN-35 (compound 5g) is an acetylcholinesterase inhibitor with an IC50 value of 5.88 μM [1].

Antiviral agent 35 (compound 4d) is a potent oral inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, apoptosis, and the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, with a CC50 greater than 800 μM, and it has anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM [1].

HDAC6-IN-35, also known as compound C4 (ZINC000077541942), is an effective HDAC6 inhibitor with an IC 50 of 4.7 μM and is capable of crossing the blood-brain barrier. It exhibits cytotoxicity against MDA-MB-231 cells with an EC 50 of 40.6 μM [1].

HSD17B13-IN-35 (compound 76) is a potent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM using estradiol as the substrate. This compound is significantly relevant in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

FO-35 is an ionizable lipid utilized in the synthesis of lipid nanoparticles (LNP). It is employed for delivering mRNA to mouse muscle and nasal mucosa, as well as to ferret lungs.

β-Amyloid (10-35), amide, is a chemical compound comprising 26 amino acids, specifically residues 10-35 of the Aβ peptide, and serves as the primary constituent of amyloid plaques in Alzheimer's disease.

GPR35 agonist 1 is a highly effective and specific GPR35/CXCR8 agonist (EC50: 5.8 nM).

β-Amyloid (25-35) is a fragment of the Alzheimer’s amyloid beta peptide Aβ(25-35), exhibiting neurotoxic effects and commonly used to establish both cellular and animal models of Alzheimer’s disease.